Live feed06:00:00·4mPRReleasevia QuantisnowJohnson & Johnson announces new ICOTYDE® (icotrokinra) data in difficult-to-treat plaque psoriasis with proven durability through 2-years, affirming its use as a powerful first line systemic therapyByQuantisnow·Wall Street's wire, on your screen.JNJ· Johnson & JohnsonHealth Care
